BIOGEN INC. DL -,0005 | 223.000 / -1.33% |
Date/Time | 01/26 / 21:58 |
Chg. / Chg.(%) | -3.000 / -1.33% |
Bid | 222.650 / 31 |
Ask | 224.050 / 31 |
Open | 227.250 |
Previous Close | 226.000 |
High | 227.750 |
Low | 221.450 |
Volume [EUR] | 216,176.200 |
Volume [Units] | 963 |
Price fixings | 43 |
ISIN | US09062X1037 |
Security | IDP |
Exchange | TradeGate |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 271.6700 | ![]() |
777,252 |
IEX | 271.70 | ![]() |
55,321 |
Cboe US | 271.79 | ![]() |
33,087 |
TradeGate | 223.000 | ![]() |
963 |
London Inter.. | 269.74 | ![]() |
500 |
Xetra | 222.95 | ![]() |
264 |
Frankfurt | 226.4000 | ![]() |
115 |
Vienna Globa.. | 222.80 | ![]() |
73 |
gettex | 223.050 | ![]() |
56 |
Stuttgart | 227.050 | ![]() |
45 |
Düsseldorf | 221.80 | ![]() |
5 |
München | 225.35 | ![]() |
0 |
Hamburg | 225.35 | ![]() |
0 |
Berlin | 221.95 | ![]() |
0 |
Hannover | 225.35 | ![]() |
0 |
Lang & Schwa.. | 222.500 | ![]() |
|
Mexico | 5,536.00 | ![]() |
10 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire
Personal area
Click on
to activate push quotes.
